Short Interest in CureVac (NASDAQ:CVAC) Grows By 10.7%

CureVac (NASDAQ:CVACGet Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 4,860,000 shares, a growth of 10.7% from the February 29th total of 4,390,000 shares. Approximately 5.3% of the company’s stock are short sold. Based on an average trading volume of 876,200 shares, the days-to-cover ratio is currently 5.5 days.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in CureVac by 588.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,813,896 shares of the company’s stock worth $26,583,000 after purchasing an additional 3,260,031 shares during the period. BlackRock Inc. lifted its holdings in shares of CureVac by 62.8% during the first quarter. BlackRock Inc. now owns 1,972,937 shares of the company’s stock worth $13,751,000 after buying an additional 761,024 shares in the last quarter. Camber Capital Management LP raised its stake in CureVac by 17.0% in the second quarter. Camber Capital Management LP now owns 1,462,500 shares of the company’s stock valued at $15,239,000 after purchasing an additional 212,500 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in CureVac in the first quarter valued at about $7,391,000. Finally, Millennium Management LLC raised its stake in CureVac by 61.6% in the fourth quarter. Millennium Management LLC now owns 866,244 shares of the company’s stock valued at $5,223,000 after purchasing an additional 330,212 shares in the last quarter. 17.26% of the stock is owned by institutional investors.

CureVac Stock Performance

Shares of CVAC traded down $0.10 during mid-day trading on Tuesday, hitting $2.88. 637,494 shares of the company’s stock were exchanged, compared to its average volume of 793,478. CureVac has a 52 week low of $2.76 and a 52 week high of $12.36. The company has a 50-day simple moving average of $3.35 and a 200 day simple moving average of $4.64. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.56 and a quick ratio of 3.41.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.

Read More

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.